BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 33778144)

  • 1. Digital PCR can provide improved
    Smitalova D; Dvorakova D; Racil Z; Romzova M
    Pract Lab Med; 2021 May; 25():e00210. PubMed ID: 33778144
    [No Abstract]   [Full Text] [Related]  

  • 2. RT-qPCR and RT-Digital PCR: A Comparison of Different Platforms for the Evaluation of Residual Disease in Chronic Myeloid Leukemia.
    Alikian M; Whale AS; Akiki S; Piechocki K; Torrado C; Myint T; Cowen S; Griffiths M; Reid AG; Apperley J; White H; Huggett JF; Foroni L
    Clin Chem; 2017 Feb; 63(2):525-531. PubMed ID: 27979961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular techniques for the personalised management of patients with chronic myeloid leukaemia.
    Alikian M; Gale RP; Apperley JF; Foroni L
    Biomol Detect Quantif; 2017 Mar; 11():4-20. PubMed ID: 28331814
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation.
    Bernardi S; Malagola M; Zanaglio C; Polverelli N; Dereli Eke E; D'Adda M; Farina M; Bucelli C; Scaffidi L; Toffoletti E; Deambrogi C; Stagno F; Bergamaschi M; Franceschini L; Abruzzese E; Divona MD; Gobbi M; Di Raimondo F; Gaidano G; Tiribelli M; Bonifacio M; Cattaneo C; Iurlo A; Russo D
    Cancer Med; 2019 May; 8(5):2041-2055. PubMed ID: 30950237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advantages of digital PCR in the detection of low abundance
    Yan Z; Sun Q; Zhang H; Han Y; Qiao J; Niu M; Zhu S; Zhao K; Wu Q; Cheng H; Cao J; Zeng L; Li Z; Xu K
    Oncol Lett; 2019 Nov; 18(5):5139-5144. PubMed ID: 31612025
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discontinuation of tyrosine kinase inhibitors based on
    Kim Y; Kim S; Lee JM; Ahn A; Yoo JW; Lee JW; Cho B; Chung NG; Kim Y; Kim M
    Front Pediatr; 2022; 10():928136. PubMed ID: 35967571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of Real-Time Quantitative PCR and Digital Droplet PCR for BCR-ABL1 Monitoring in Patients with Chronic Myeloid Leukemia.
    Franke GN; Maier J; Wildenberger K; Cross M; Giles FJ; Müller MC; Hochhaus A; Niederwieser D; Lange T
    J Mol Diagn; 2020 Jan; 22(1):81-89. PubMed ID: 31669230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Droplet digital PCR for BCR/ABL(P210) detection of chronic myeloid leukemia: A high sensitive method of the minimal residual disease and disease progression.
    Wang WJ; Zheng CF; Liu Z; Tan YH; Chen XH; Zhao BL; Li GX; Xu ZF; Ren FG; Zhang YF; Chang JM; Wang HW
    Eur J Haematol; 2018 Sep; 101(3):291-296. PubMed ID: 29691899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Comparison of BCR::ABL (P210) mRNA levels detected by dPCR and qPCR methods in patients with chronic myeloid leukemia].
    Gao HL; Hao Y; Chen WM; Li LD; Wang X; Qin YZ; Jiang Q
    Zhonghua Xue Ye Xue Za Zhi; 2023 Nov; 44(11):906-910. PubMed ID: 38185519
    [No Abstract]   [Full Text] [Related]  

  • 10. Digital PCR for
    Kockerols CCB; Valk PJM; Levin MD; Pallisgaard N; Cornelissen JJ; Westerweel PE
    Hemasphere; 2020 Dec; 4(6):e496. PubMed ID: 33283168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Minimal Residual Disease Detection at RNA and Leukemic Stem Cell (LSC) Levels: Comparison of RT-qPCR, d-PCR and CD26+ Stem Cell Measurements in Chronic Myeloid Leukemia (CML) Patients in Deep Molecular Response (DMR).
    Abruzzese E; Bocchia M; Trawinska MM; Raspadori D; Bondanini F; Sicuranza A; Pacelli P; Re F; Cavalleri A; Farina M; Malagola M; Russo D; De Fabritiis P; Bernardi S
    Cancers (Basel); 2023 Aug; 15(16):. PubMed ID: 37627140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Droplet Digital PCR for
    Bochicchio MT; Petiti J; Berchialla P; Izzo B; Giugliano E; Ottaviani E; Errichiello S; Rege-Cambrin G; Venturi C; Luciano L; Daraio F; Calistri D; Rosti G; Saglio G; Martinelli G; Pane F; Cilloni D; Gottardi EM; Fava C
    Cancers (Basel); 2021 Oct; 13(21):. PubMed ID: 34771634
    [No Abstract]   [Full Text] [Related]  

  • 13. Comparison of molecular responses based on BCR-ABL1% (IS) results from an in-house TaqMan-based qPCR versus Xpert(®) assay in CML patients on tyrosine kinase inhibitor therapy.
    Boeckx N; Laer CV; Roover JD; Wilmsen B; Bruyninckx K; Pauwels S
    Acta Clin Belg; 2015 Aug; 70(4):237-43. PubMed ID: 26166681
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RT-qPCR versus Digital PCR: How Do They Impact Differently on Clinical Management of Chronic Myeloid Leukemia Patients?
    Zanaglio C; Bernardi S; Gandolfi L; Farina M; Re F; Polverelli N; Zollner T; Turra A; Morello E; Malagola M; Russo D
    Case Rep Oncol; 2020; 13(3):1263-1269. PubMed ID: 33250741
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of Droplet Digital PCR versus qPCR Measurements on the International Scale for the Molecular Monitoring of Chronic Myeloid Leukemia Patients.
    Cortés AA; Olmedillas S; Serrano-López J; Lainez-González D; Castaño T; Iñiguez R; Lopez-Lorenzo JL; García A; Atance M; Sánchez RNS; Lopez CB; Arranz MG; Sillero PL; Alonso-Dominguez JM
    Mol Diagn Ther; 2020 Oct; 24(5):593-600. PubMed ID: 32875515
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analytical Validation of a Highly Sensitive, Multiplexed Chronic Myeloid Leukemia Monitoring System Targeting BCR-ABL1 RNA.
    Brown JT; Beldorth IJ; Laosinchai-Wolf W; Fahey ME; Jefferson KL; Ruskin AK; Roth JJ; Cai L; Watt CD; Press RD; Yang F; Hedges JB; Andruss BF
    J Mol Diagn; 2019 Jul; 21(4):718-733. PubMed ID: 31026597
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of BCR::ABL1 transcript type on RT-qPCR amplification performance and molecular response to therapy.
    Salmon M; White HE; Zizkova H; Gottschalk A; Motlova E; Cerveira N; Colomer D; Coriu D; Franke GN; Gottardi E; Izzo B; Jurcek T; Lion T; Schäfer V; Venturi C; Vigneri P; Zawada M; Zuna J; Hovorkova L; Koblihova J; Klamova H; Markova MS; Srbova D; Benesova A; Polivkova V; Zackova D; Mayer J; Roeder I; Glauche I; Ernst T; Hochhaus A; Polakova KM; Cross NCP
    Leukemia; 2022 Jul; 36(7):1879-1886. PubMed ID: 35676453
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of droplet digital polymerase chain reaction for measuring BCR-ABL1 in chronic myeloid leukaemia in an international interlaboratory study.
    Scott S; Cartwright A; Francis S; Whitby L; Sanzone AP; Mulder A; Galimberti S; Dulucq S; Mauté C; Lauricella C; Salmon M; Rose S; Willoughby J; Boeckx N; Pallisgaard N; Maier J; Leibundgut EO; Zizkova H; Ling Goh L; Duong C; Tang WF; Ma E; Shivakumar Y; Beppu L; Bhagavatula P; Chantry A
    Br J Haematol; 2021 Jul; 194(1):53-60. PubMed ID: 34114218
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Variant-specific discrepancy when quantitating BCR-ABL1 e13a2 and e14a2 transcripts using the Europe Against Cancer qPCR assay.
    Kjaer L; Skov V; Andersen MT; Aggerholm A; Clair P; Gniot M; Soeby K; Udby L; Dorff MH; Hasselbalch H; Pallisgaard N
    Eur J Haematol; 2019 Jul; 103(1):26-34. PubMed ID: 30985947
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of major BCR-ABL1 mRNA by digital polymerase chain reaction is useful for prediction of international scale.
    Furuya D; Moriai M; Koizumi Y; Endo T; Asanuma K; Yanagihara N; Takahashi S
    Int J Clin Oncol; 2019 Jul; 24(7):871-875. PubMed ID: 30798394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.